Table 3.

Effects of Notch-targeted therapeutics to reverse drug efflux-dependent drug resistance. Summary of the pre-clinical studies

Notch-targeted therapeutics	Target*	Mechanism of action	Reverse resistance to	Model	Cancer context	Ref.
PF-03084014 (γ-secretase inhibitor)	Notch signaling	Downregulation of MDR1/ABCB1 and ABCC2 transporters	Docetaxel (chemo-therapeutic agent)	Preclinical study: mice	Breast	[123]
shRNA Notch3	Notch3	Downregulation of MDR1/ABCB1 transporter	Carboplatin (chemo-therapeutic agent)	Preclinical study: cell lines	Ovarian	[200]
lncRNA MALAT1	Notch1	Downregulation of MRP1/ABCC1 transporter	Cisplatin (chemo-therapeutic agent)	Preclinical study: mice	Ovarian	[204]

*Notch receptor or ligand involved, when specified.